Review on Breast Cancer
| International Journal of Humanities and Social Science |
| © 2020 by SSRG - IJHSS Journal |
| Volume 7 Issue 4 |
| Year of Publication : 2020 |
| Authors : Dharampal Singh |
10.14445/23942703/IJHSS-V7I4P106
How to Cite?
Dharampal Singh, "Review on Breast Cancer," SSRG International Journal of Humanities and Social Science, vol. 7, no. 4, pp. 31-37, 2020. Crossref, https://doi.org/10.14445/23942703/IJHSS-V7I4P106
Abstract:
In this research paper, our primary focus on breast cancer and a survey of breast cancer (B.C.),& also comparison the male and female breast cancer.
This research article very useful/fruitful for new researchers.
Keywords:
Breast Cancer
References:
[1] A. P. Forrest, H. J. Stewart, D. Everington, R. J. Prescott, C. S. McArdle, A. N. Harnett, D. C. Smith, W. D. George, and S. C. T. B. Group, “Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the scoish trial,” The Lancet, vol. 348, no. 9029, pp. 708–713, 1996.
[2] J. L. Kelsey, M. D. Gammon, and E. M. John, “Reproductive factors and breast cancer.,” Epidemiologic reviews, vol. 15, no. 1, p. 36, 1993.
[3] C. DeSantis, J. Ma, L. Bryan, and A. Jemal, “Breast cancer statistics, 2013,” CA: a cancer journal for clinicians, vol. 64, no. 1, pp. 52–62, 2014.
[4] M. C. Pike, D. V. Spicer, L. Dahmoush, and M. F. Press, “Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.,” Epidemiologic reviews, vol. 15, no. 1, p. 17, 1993.
[5] T. J. Key, P. K. Verkasalo, and E. Banks, “Epidemiology of breast cancer,” e lancet oncology, vol. 2, no. 3, pp. 133–140, 2001.
[6] C. G. on Hormonal Factors in Breast Cancer et al., “Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer,” The Lancet, vol. 350, no. 9084, pp. 1047–1059, 1997.
[7] A. E. Giuliano, R. C. Jones, M. Brennan, and R. Statman, “Sentinel lymphadenectomy in breast cancer.,” Journal of Clinical Oncology, vol. 15, no. 6, pp. 2345–2350, 1997.
[8] W. D. Foulkes, I. E. Smith, and J. S. Reis-Filho, “Triple-negative breast cancer,” New England journal of medicine, vol. 363, no. 20, pp. 1938–1948, 2010.
[9] D. F. Easton, D. Ford, and D. T. Bishop, “Breast and ovarian cancer incidence in brca1-mutation carriers. breast cancer linkage
consortium.,” American journal of human genetics, vol. 56, no. 1, p. 265, 1995.
[10] C. G. on Hormonal Factors in Breast Cancer et al., “Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies,” The Lancet, vol. 347, no. 9017, pp. 1713–1727, 1996.
[11] L. Fan, K. Strasser-Weippl, J.-J. Li, J. St Louis, D. M. Finkelstein, K.-D. Yu,W.-Q. Chen, Z.-M. Shao, and P. E. Goss, “Breast cancer in china,”
The lancet oncology, vol. 15, no. 7, pp. e279–e289, 2014.
[12] J. R. Harris, M. E. Lippman, U. Veronesi, and W. Willett, “Breast cancer,” New England Journal of Medicine, vol. 327, no. 5, pp. 319–328,1992.
[13] A. M¨uller, B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, et al., “Involvement
of chemokine receptors in breast cancer metastasis,” nature, vol. 410, no. 6824, pp. 50–56, 2001.
[14] S. H. Ahn and B. C. S. Korean, “Clinical characteristics of breast cancer patients in korea in 2000.,” Archives of surgery (Chicago, Ill.: 1960), vol. 139, no. 1, p. 27, 2004.
[15] H. Kennecke, R. Yerushalmi, R. Woods, M. C. U. Cheang, D. Voduc, C. H. Speers, T. O. Nielsen, and K. Gelmon, “Metastatic behavior
of breast cancer subtypes,” Journal of clinical oncology, vol. 28, no. 20, pp. 3271–3277, 2010.
[16] R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, G. Micklem, et al., “Identication
of the breast cancer susceptibility gene brca2,” Nature, vol. 378, no. 6559, pp. 789–792, 1995. ISSN:2394-2703
[17] M. V. Iorio, M. Ferracin, C.-G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, et al., “Microrna gene expression deregulation in human breast cancer,” Cancer research, vol. 65, no. 16, pp. 7065–7070, 2005.
[18] L. Bernstein and R. K. Ross, “Endogenous hormones and breast cancer risk.,” Epidemiologic reviews, vol. 15, no. 1, pp. 48–65, 1993.
[19] W. D. Dupont and D. L. Page, “Risk factors for breast cancer in women with proliferative breast disease,” New England Journal of Medicine, vol. 312, no. 3, pp. 146–151, 1985.
[20] E. A. Rakha, M. E. El-Sayed, A. R. Green, A. H. Lee, J. F. Robertson, and I. O. Ellis, “Prognostic markers in triple-negative breast cancer,”
Cancer, vol. 109, no. 1, pp. 25–32, 2007.
[21] I. S. Fentiman, A. Fourquet, and G. N. Hortobagyi, “Male breast cancer,” The Lancet, vol. 367, no. 9510, pp. 595–604, 2006.
[22] I. Hedenfalk, D. Duggan, Y. Chen, M. Radmacher, M. Bittner, R. Simon, P. Meltzer, B. Gusterson, M. Esteller, M. Raeld, et al., “Gene-expression proles in hereditary breast cancer,” New England Journal of Medicine, vol. 344, no. 8, pp. 539–548, 2001.
[23] M. Clemons and P. Goss, “Estrogen and the risk of breast cancer,” New England Journal of Medicine, vol. 344, no. 4, pp. 276–285, 2001.
[24] J. L. Kelsey, “Breast cancer epidemiology: summary and future directions.,” Epidemiologic Reviews, vol. 15, no. 1, p. 256, 1993.
[25] P. C. Gøtzsche and K. J. Jørgensen, “Screening for breast cancer with mammography,” Cochrane database of systematic reviews, no. 6, 2013.
[26] K. Polyak et al., “Heterogeneity in breast cancer,” The Journal of clinical investigation, vol. 121, no. 10, pp. 3786–3788, 2011.
[27] I. E. Smith and M. Dowse, “Aromatase inhibitors in breast cancer,” New England Journal of Medicine, vol. 348, no. 24, pp. 2431–2442, 2003.
[28] C. K. Osborne, “Tamoxifen in the treatment of breast cancer,” New England Journal of Medicine, vol. 339, no. 22, pp. 1609–1618, 1998.
[29] S. Modi, C. Saura, T. Yamashita, Y. H. Park, S.- B. Kim, K. Tamura, F. Andre, H. Iwata, Y. Ito, J. Tsurutani, et al., “Trastuzumab deruxtecan
in previously treated her2-positive breast cancer,” New England Journal of Medicine, vol. 382, no. 7, pp. 610–621, 2020.
[30] R. K. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. A. Hurvitz, N. U. Lin, V. Borges, V. Abramson, C. Anders, et al., “Tucatinib, trastuzumab, and capecitabine for her2-positive metastatic breast cancer,” New England Journal of Medicine, vol. 382, no. 7, pp. 597–609, 2020.
[31] K. P. Lowry, A. Trentham-Dietz, C. B. Schechter, O. Alagoz, W. E. Barlow, E. S. Burnside, E. F. Conant, J. M. Hampton, H. Huang, K. Kerlikowske, et al., “Long-term outcomes and cost-eectiveness of breast cancer screening with digital breast tomosynthesis in the united states,” JNCI: Journal of
the National Cancer Institute, vol. 112, no. 6, pp. 582–589, 2020.
[32] S. Yadav, D. Karam, I. Bin Riaz, H. Xie, U. Durani, N. Duma, K. V. Giridhar, T. J. Hieken, J. C. Boughey, R. W. Muer, et al., “Male breast cancer in the united states: Treatment patterns and prognostic factors in the 21st century,” Cancer, vol. 126, no. 1, pp. 26–36, 2020.
[33] B. S. Hill, A. Sarnella, G. D’Avino, and A. Zannetti, “Recruitment of stromal cells into tumour microenvironment promote the ISSN:2394-2703 metastatic spread of breast cancer,” in Seminars in cancer biology, vol. 60, pp. 202–213, Elsevier, 2020.
[34] S. Liu, R. Gonz´alez-Prieto, M. Zhang, P. P. Geurink, R. Kooij, P. V. Iyengar, M. van Dinther, E. Bos, X. Zhang, S. E. Le D´ev´edec, et al., “Deubiquitinase activity proling identies uchl1 as a candidate oncoprotein that promotes tgf -induced breast cancer metastasis,” Clinical Cancer Research, vol. 26, no. 6, pp. 1460–1473, 2020.
[35] J. Luo, X. Chen, J. E. Manson, A. H. Shadyab, J.Wactawski-Wende, M. Vitolins, T. E. Rohan, T.-Y. D. Cheng, Z. Zhang, L. Qi, et al., “Birth weight, weight over the adult life course and risk of breast cancer,” International journal of cancer, vol. 147, no. 1, pp. 65–75, 2020.
[36] M. Mutebi, B. O. Anderson, C. Duggan, C. Adebamowo, G. Agarwal, Z. Ali, P. Bird, J.-M. Bourque, R. DeBoer, L. H. Gebrim, et al., “Breast cancer treatment: A phased approach to implementation,” Cancer, vol. 126, pp. 2365–2378, 2020.